Urszula M. Polanska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Urszula M. Polanska has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Jamal Saeh
Projects, Oncology R&D, AstraZeneca, Boston, Massachusetts
41 shared publications - Jelena Urosevic
Oncology Targeted Discovery, Oncology R&D, AstraZeneca, Cambridge, UK
41 shared publications - Azusa Tanimoto
Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
40 shared publications - C. Allison Stewart
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
40 shared publications - Carl Michael Gay
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
40 shared publications - Carminia Maria Della Corte
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80131 Naples, Italy
40 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary Figure 3 shows the combination of AZD2811 and BCL2 inhibitor enhances apoptosis and cell death.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary Figure 3 shows the combination of AZD2811 and BCL2 inhibitor enhances apoptosis and cell death.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary Figure 1 shows BCL2 is a strong biomarker of resistance to AURK inhibition in SCLC.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary Figure 1 shows BCL2 is a strong biomarker of resistance to AURK inhibition in SCLC.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary Figure 2 shows polyploidy and apoptosis are inhibited by high BCL2 levels
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary Figure 2 shows polyploidy and apoptosis are inhibited by high BCL2 levels
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary Figure 4 shows the combination of AZD2811NP with venetoclax is well tolerated in mice and less efficacious in SCLC models with low BCL2 expression.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary Figure 4 shows the combination of AZD2811NP with venetoclax is well tolerated in mice and less efficacious in SCLC models with low BCL2 expression.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary table shows AZD2811 sensitivity, transcriptomic and proteomic profiles of SCLC cell lines
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Supplementary table shows AZD2811 sensitivity, transcriptomic and proteomic profiles of SCLC cell lines
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Purpose:Therapeutic resistance to frontline therapy develops rapidly in small cell lung cancer (SCLC). Treatment options are also limited by the lack of targetable driver mutations. Therefore, there is an unmet need for developing better therapeutic strategies and biomarkers of response. Aurora kinase B (AURKB) inhibition exploits an inherent genomic vulnerability in SCLC and is a promising therapeutic approach. Here, we identify biomarkers of response and develop rational combinations with AURKB inhibition to improve treatment efficacy.Experimental Design:Selective AURKB inhibitor AZD2811 was profiled in a large panel of SCLC cell lines (n = 57) and patient-derived xenograft (PDX) models. Proteomic and transcriptomic profiles were analyzed to identify candidate biomarkers of response and resistance. Effects on polyploidy, DNA damage, and apoptosis were measured by flow cytometry and Western blotting. Rational drug combinations were validated in SCLC cell lines and PDX models.Results:AZD2811 showed potent growth inhibitory activity in a subset of SCLC, often characterized by, but not limited to, high cMYC expression. Importantly, high BCL2 expression predicted resistance to AURKB inhibitor response in SCLC, independent of cMYC status. AZD2811-induced DNA damage and apoptosis were suppressed by high BCL2 levels, while combining AZD2811 with a BCL2 inhibitor significantly sensitized resistant models. In vivo, sustained tumor growth reduction and regression was achieved even with intermittent dosing of AZD2811 and venetoclax, an FDA-approved BCL2 inhibitor.Conclusions:BCL2 inhibition overcomes intrinsic resistance and enhances sensitivity to AURKB inhibition in SCLC preclinical models.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Purpose:Therapeutic resistance to frontline therapy develops rapidly in small cell lung cancer (SCLC). Treatment options are also limited by the lack of targetable driver mutations. Therefore, there is an unmet need for developing better therapeutic strategies and biomarkers of response. Aurora kinase B (AURKB) inhibition exploits an inherent genomic vulnerability in SCLC and is a promising therapeutic approach. Here, we identify biomarkers of response and develop rational combinations with AURKB inhibition to improve treatment efficacy.Experimental Design:Selective AURKB inhibitor AZD2811 was profiled in a large panel of SCLC cell lines (n = 57) and patient-derived xenograft (PDX) models. Proteomic and transcriptomic profiles were analyzed to identify candidate biomarkers of response and resistance. Effects on polyploidy, DNA damage, and apoptosis were measured by flow cytometry and Western blotting. Rational drug combinations were validated in SCLC cell lines and PDX models.Results:AZD2811 showed potent growth inhibitory activity in a subset of SCLC, often characterized by, but not limited to, high cMYC expression. Importantly, high BCL2 expression predicted resistance to AURKB inhibitor response in SCLC, independent of cMYC status. AZD2811-induced DNA damage and apoptosis were suppressed by high BCL2 levels, while combining AZD2811 with a BCL2 inhibitor significantly sensitized resistant models. In vivo, sustained tumor growth reduction and regression was achieved even with intermittent dosing of AZD2811 and venetoclax, an FDA-approved BCL2 inhibitor.Conclusions:BCL2 inhibition overcomes intrinsic resistance and enhances sensitivity to AURKB inhibition in SCLC preclinical models.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer
Supplementary Figure 3 shows the combination of AZD2811 and BCL2 inhibitor enhances apoptosis and cell death.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer
Supplementary Figure 3 shows the combination of AZD2811 and BCL2 inhibitor enhances apoptosis and cell death.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer
Supplementary Figure 3 shows the combination of AZD2811 and BCL2 inhibitor enhances apoptosis and cell death.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer
Supplementary Figure 3 shows the combination of AZD2811 and BCL2 inhibitor enhances apoptosis and cell death.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer
Supplementary Figure 2 shows polyploidy and apoptosis are inhibited by high BCL2 levels
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer
Supplementary Figure 2 shows polyploidy and apoptosis are inhibited by high BCL2 levels
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer
Supplementary Figure 2 shows polyploidy and apoptosis are inhibited by high BCL2 levels
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer
Supplementary Figure 2 shows polyploidy and apoptosis are inhibited by high BCL2 levels